These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 28900832)

  • 1. Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics.
    Prah MA; Al-Gizawiy MM; Mueller WM; Cochran EJ; Hoffmann RG; Connelly JM; Schmainda KM
    J Neurooncol; 2018 Jan; 136(1):13-21. PubMed ID: 28900832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinguishing Tumor Recurrence From Radiation Necrosis in Treated Glioblastoma Using Multiparametric MRI.
    Feng A; Yuan P; Huang T; Li L; Lyu J
    Acad Radiol; 2022 Sep; 29(9):1320-1331. PubMed ID: 34896001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
    Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
    BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiparametric imaging-based differentiation of lymphoma and glioblastoma: using T1-perfusion, diffusion, and susceptibility-weighted MRI.
    Saini J; Kumar Gupta P; Awasthi A; Pandey CM; Singh A; Patir R; Ahlawat S; Sadashiva N; Mahadevan A; Kumar Gupta R
    Clin Radiol; 2018 Nov; 73(11):986.e7-986.e15. PubMed ID: 30197047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.
    Boonzaier NR; Larkin TJ; Matys T; van der Hoorn A; Yan JL; Price SJ
    Radiology; 2017 Jul; 284(1):180-190. PubMed ID: 28240563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of FDG-PET/MRI, FDG-PET/CT, and Dynamic Susceptibility Contrast Perfusion MRI in Differentiating Radiation Necrosis from Tumor Recurrence in Glioblastomas.
    Hojjati M; Badve C; Garg V; Tatsuoka C; Rogers L; Sloan A; Faulhaber P; Ros PR; Wolansky LJ
    J Neuroimaging; 2018 Jan; 28(1):118-125. PubMed ID: 28718993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
    Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
    Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
    Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation of progressive disease from pseudoprogression using 3D PCASL and DSC perfusion MRI in patients with glioblastoma.
    Manning P; Daghighi S; Rajaratnam MK; Parthiban S; Bahrami N; Dale AM; Bolar D; Piccioni DE; McDonald CR; Farid N
    J Neurooncol; 2020 May; 147(3):681-690. PubMed ID: 32239431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
    Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
    Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of Percentage Signal Recovery and Baseline Signal in DSC-MRI Optimized for Relative CBV Measurement for Differentiating Glioblastoma, Lymphoma, Metastasis, and Meningioma.
    Lee MD; Baird GL; Bell LC; Quarles CC; Boxerman JL
    AJNR Am J Neuroradiol; 2019 Sep; 40(9):1445-1450. PubMed ID: 31371360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of Glioblastoma and Solitary Brain Metastasis by Gradient of Relative Cerebral Blood Volume in the Peritumoral Brain Zone Derived from Dynamic Susceptibility Contrast Perfusion Magnetic Resonance Imaging.
    She D; Xing Z; Cao D
    J Comput Assist Tomogr; 2019; 43(1):13-17. PubMed ID: 30015801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients.
    Kim JY; Park JE; Jo Y; Shim WH; Nam SJ; Kim JH; Yoo RE; Choi SH; Kim HS
    Neuro Oncol; 2019 Feb; 21(3):404-414. PubMed ID: 30107606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of combined visualization of MR diffusion and perfusion maps in glioblastoma.
    Deike K; Wiestler B; Graf M; Reimer C; Floca RO; Bäumer P; Kickingereder P; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    J Neurooncol; 2016 Feb; 126(3):463-72. PubMed ID: 26518541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interval Change in Diffusion and Perfusion MRI Parameters for the Assessment of Pseudoprogression in Cerebral Metastases Treated With Stereotactic Radiation.
    Knitter JR; Erly WK; Stea BD; Lemole GM; Germano IM; Doshi AH; Nael K
    AJR Am J Roentgenol; 2018 Jul; 211(1):168-175. PubMed ID: 29708785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a Single-Dose, Low-Flip-Angle-Based CBV Threshold for Fractional Tumor Burden Mapping in Recurrent Glioblastoma.
    Anil A; Stokes AM; Karis JP; Bell LC; Eschbacher J; Jennings K; Prah MA; Hu LS; Boxerman JL; Schmainda KM; Quarles CC
    AJNR Am J Neuroradiol; 2024 Oct; 45(10):1545-1551. PubMed ID: 38782593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ventricle contact is associated with lower survival and increased peritumoral perfusion in glioblastoma.
    van Dijken BRJ; Jan van Laar P; Li C; Yan JL; Boonzaier NR; Price SJ; ; van der Hoorn A
    J Neurosurg; 2018 Oct; 131(3):717-723. PubMed ID: 30485234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiparametric MRI for Differentiation of Radiation Necrosis From Recurrent Tumor in Patients With Treated Glioblastoma.
    Nael K; Bauer AH; Hormigo A; Lemole M; Germano IM; Puig J; Stea B
    AJR Am J Roentgenol; 2018 Jan; 210(1):18-23. PubMed ID: 28952810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
    Kim JH; Choi SH; Ryoo I; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    PLoS One; 2014; 9(11):e113587. PubMed ID: 25419975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.
    Ken S; Deviers A; Filleron T; Catalaa I; Lotterie JA; Khalifa J; Lubrano V; Berry I; Péran P; Celsis P; Moyal EC; Laprie A
    J Neurooncol; 2015 Sep; 124(3):465-73. PubMed ID: 26189058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.